P
PolyPid Ltd. (PYPD)
4.28
0.00 (0.00%)
Get all premium features to the best stock analysis tool
4.28
0.00 (0.00%)
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
| Name | Position |
|---|---|
| Dr. Jean-Marc Hagai Pharm.D. | Chief Commercial Officer |
| Dr. Nurit Tweezer-Zaks M.B.A., M.D. | Chief Medical Officer |
| Mr. Jonny Missulawin | Chief Financial Officer |
| Mr. Ori Warshavsky | Chief Operating Officer - US |
| Mr. Tal Vilnai | General Counsel & Corporate Secretary |
| Ms. Dalit Hazan | Deputy CEO and Executive VP of R&D, Clinical & Regulatory Affairs |
| Ms. Dikla Czaczkes Akselbrad | CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2025-12-31 | 6-K | ea0271262-6k_polypid.htm |
| 2025-12-16 | 6-K | ea0269841-6k_polypid.htm |
| 2025-12-03 | 6-K | ea0268313-6k_polypid.htm |
| 2025-11-12 | 6-K | ea0265276-6k_polypid.htm |
| 2025-09-16 | 6-K | ea0257530-6k_polypid.htm |
| 2025-08-13 | 6-K | ea0253019-6k_polypid.htm |
| 2025-08-12 | 6-K | ea0252624-6k_polypid.htm |
| 2025-08-04 | CORRESP | filename1.htm |
| 2025-07-29 | F-3 | ea0250584-f3_polypid.htm |
| 2025-07-15 | 6-K | ea0248999-6k_polypid.htm |
| Ms. Maria Rubin |
| Executive Vice President of Operations |
| Ms. Rivi Lev-ari | Vice President of Human Resource |